Related Experiment Video
Updated: Jan 9, 2026

Differentiation of Human Pluripotent Stem Cells Into Pancreatic Beta-Cell Precursors in a 2D Culture System
Published on: December 16, 2021
Limitations in PPARα-dependent mitochondrial programming restrain the differentiation of human stem cell-derived β
Anne C Lietzke1,2, Emily M Walker1, Elizabeth Bealer3
1Division of Metabolism, Endocrinology and Diabetes and Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Abstract:
Pluripotent stem cell (SC)-derived islets offer hope as a renewable source for β cell replacement for type 1 diabetes (T1D), yet functional and metabolic immaturity may limit their long-term therapeutic potential. Here, we show that limitations in mitochondrial transcriptional programming impede the formation of SC-derived β (SC-β) cells. Utilizing transcriptomic profiling, assessments of chromatin accessibility, mitochondrial phenotyping, and lipidomics analyses, we observe that SC-β cells exhibit reduced oxidative and mitochondrial fatty acid metabolism compared to primary human islets that are related to limitations in key mitochondrial transcriptional networks. Surprisingly, we find that reductions in glucose-stimulated mitochondrial respiration in SC-islets were not associated with alterations in mitochondrial mass, structure, or genome integrity. In contrast, SC-islets show limited expression of targets of PPARα, which regulate mitochondrial programming, yet whose functions in β cell differentiation are unknown. Importantly, treatment with WY14643, a potent PPARα agonist, induces expression of mitochondrial targets, improves insulin secretion, and increases the formation of SC-β cells both in vitro and following transplantation. Thus, PPARα-dependent mitochondrial programming promotes the differentiation of SC-β cells and may be a promising target to improve β cell replacement efforts for T1D.
Insights
Pluripotent stem cell-derived beta cells show immature mitochondrial function, hindering type 1 diabetes (T1D) treatment. Activating PPARα enhances mitochondrial programming, improving beta cell development and insulin secretion for T1D therapy.
Area of Science:
- Cell Biology
- Metabolic Disease Research
- Regenerative Medicine
Background:
- Pluripotent stem cell-derived islets are a potential renewable source for beta cell replacement in type 1 diabetes (T1D).
- Functional and metabolic immaturity of these cells may limit their therapeutic efficacy.
- Mitochondrial transcriptional programming is crucial for cellular function and differentiation.
Purpose of the Study:
- To investigate the role of mitochondrial transcriptional programming in the functional and metabolic immaturity of stem cell-derived beta (SC-β) cells.
- To identify factors limiting SC-β cell development and function.
- To explore therapeutic strategies to enhance SC-β cell maturation and efficacy for T1D treatment.
Main Methods:
- Transcriptomic profiling to analyze gene expression patterns.
- Chromatin accessibility assays to assess regulatory element activity.
- Mitochondrial phenotyping and lipidomics to evaluate metabolic function.
- In vitro and in vivo studies using PPARα agonist (WY14643) treatment.
Main Results:
- SC-β cells exhibit reduced oxidative and mitochondrial fatty acid metabolism compared to primary human islets due to impaired mitochondrial transcriptional networks.
- Reduced glucose-stimulated mitochondrial respiration in SC-islets was not linked to changes in mitochondrial mass, structure, or genome integrity.
- Limited expression of PPARα targets was observed in SC-islets, suggesting a role in mitochondrial programming and beta cell differentiation.
- PPARα agonist treatment enhanced mitochondrial gene expression, improved insulin secretion, and increased SC-β cell formation in vitro and after transplantation.
Conclusions:
- Impaired mitochondrial transcriptional programming, specifically involving PPARα, limits the functional maturation of stem cell-derived beta cells.
- PPARα activation represents a promising therapeutic target to improve the differentiation and function of SC-β cells for T1D replacement therapy.
- Enhancing mitochondrial programming is key to overcoming the limitations of current stem cell-derived beta cell therapies for type 1 diabetes.
Related Concept Videos
Tissue Renewal without Stem Cells
However, failure of such a system...
Forced Transdifferentiation
Artificial...
iPS Cell Differentiation

